Casper Sleep Closes in on IPO: Should Investors Be Worried?

By Chris Lange Published Feb 5, 10:45AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Casper Sleep Closes in on IPO: Should Investors Be Worried? — © GeorgeRudy / Getty Images

Casper Sleep has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company intends to price its 8.35 million shares in the range of $12 to $13 apiece, down notably from its previous expected price range of $17 to $19. Casper has an overallotment option for an additional 1.253 million shares. At the maximum price, the entire offering now is valued up to $124.8 million. The company intends to list its shares on the New York Stock Exchange under the symbol CSPR.

Look for the company to price its offering Wednesday night and to enter the markets Thursday morning.

One of the main takeaways here is that Casper’s new price for the offering puts the company’s valuation at roughly half a billion. It doesn’t help that the company cut its valuation to get here as well. Keep in mind that it had a valuation over a billion in the past year, when it was going through its funding in the private markets. Going forward, this means that the pre-IPO buyers should be concerned about the economics of this company.

The underwriters for the offering are Morgan Stanley, Goldman Sachs, Jefferies, Merrill Lynch, UBS Investment Bank, Citigroup, Piper Sandler and Guggenheim Securities.

Casper sells mattresses, pillows, blankets and other sleep-related items, both online and in retail locations. The company has served 1.4 million customers in seven countries in its first five years.

[nativounit]

It’s no secret that the “sleep economy” is growing, as consumers spend more on wellness and are becoming more aware of the importance of sleep. This has been part of a broader trend as more consumers are pursuing healthier lifestyles.

In the filing, the company detailed:

In our first five years, Casper has experienced rapid growth. We believe our consumer focus, innovative products, and multichannel go-to-market strategy differentiate us both from legacy competitors and new entrants. For the years 2018, 2017, and 2016, our net revenue was $357.9 million, $250.9 million, and $169.1 million, respectively, representing a 45.5% compound annual growth rate, or CAGR, and for the nine months ended September 30, 2019 and 2018, our net revenue was $312.3 million and $259.7 million, respectively, representing 20.3% year-over-year growth.

The company intends to use the net proceeds from this offering for working capital, to fund growth and for other general corporate purposes.

[recirclink id= 643400]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.